BR9909322A - Derivados de sulfonilamino que inibem metaloproteinases de degradação de matriz - Google Patents
Derivados de sulfonilamino que inibem metaloproteinases de degradação de matrizInfo
- Publication number
- BR9909322A BR9909322A BR9909322-7A BR9909322A BR9909322A BR 9909322 A BR9909322 A BR 9909322A BR 9909322 A BR9909322 A BR 9909322A BR 9909322 A BR9909322 A BR 9909322A
- Authority
- BR
- Brazil
- Prior art keywords
- nitrogen
- heterocyclylalkyl
- aralkyl
- alkyl
- heteroarylalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Patente de Invenção: <B>"DERIVADOS DE SULFONILAMINO QUE INIBEM METALOPROTEINASES DE DEGRADAçãO DE MATRIZ"<D>. Compostos de fórmula I na qual W é -OH ou -NHOH; X é a) um radical heterocíclico não-substituído ou substituído, selecionado do grupo consistindo em pirrolidinila, pirrolila, pirazolila, oxetanila, pirazolinila, imidazolinila, imidazolidinila, oxazolila, oxazolidinila, isoxazolinila, isoxazolila, tiazolila, tiadiazolila, tiazolidinila, isotiazolila, isotiazolidinila, furila, tetrahidrofurila, oxadiazolila, piperidinila, piperazinila, 2-oxopiperazinila, 2-oxopiperidinila, 2-oxopirrolodinila, 2-oxoazepinila, azepinila, 4-piperidinila, piridila, pirazinila, piridazinila, tetrahidropiranila, morfolinila, tiamorfolinila, sulfóxido de tiamorfolinila, sulfona de tiamorfolinila, 1,3-dioxolano, tetrahidro-1,1-dioxotienila, benzotiazolila, benzoxazolila, quinuclidinila, quinolinila, tetrahidroisoquinolinila, isoquinolinila, benzimidazolila, benzopiranila, idolizinila, benzofurila, cromonila, cumarinila, benzopiranila, cinolinila, quinoxalinila, indazolila, pirrolopiridila, furopiridinila, dihidrobenzoisotiazolila, dihidroquinazozolinila, tetrahidroquinazolinil e sistemas de anel tricíclico de 10 a 15 membros, que têm pelo menos um heteroátomo em pelo menos um anel contendo átomo de carbono, no qual cada anel do radical heterocíclico contendo um heteroátomo pode ter 1, 2 ou 3 heteroátomos selecionados dos átomos de nitrogênio, átomos de oxigênio e átomos de súrfur; com a condição de que quando X é um radical heterocíclico contendo nitrogênio, o radical heterocíclico é ligado à porção de (CH~ 2~)~ m~ por um nitrogênio de anel e a condição de que os heteroátomos de nitrogênio e enxofre do radical heterocíclico podem também ser oxidizados; b) -NR~ 1~SO~ 2~R~ 2~, no qual R~ 1~ é hidrogênio, alquila, heterociclialquila, aralquila ou heteroarilalquila e R2 é hidrogênio, alquila, heterociclilalquila, aralquila, heteroarilalquila, arila ou heteroarila; c) heterociclialquiltio; d) -CONR~ 2~R~ 3~, no qual R~ 2~ e R~ 3~ tomados juntos com o átomo de nitrogênio ao qual eles são ligados formam um anel de 5 a 7 membros, que pode opcionalmente conter outro heteroátomo selecionado de oxigênio, nitrogênio e enxofre; ou e) -NR~ 1~COR~ 2~, no qual R~ 1~ é hidrogênio, alquila, heterociclilalquila, aralquila ou heteroarilalquila e R~ 2~ é hidrogênio, heterociclilalquila, aralquila, heteroarilalquila ou arila; Y é carbono, nitrogênio, oxigênio ou enxofre, contanto que quando Y é carbono, n é 2; Z é alquila, arila, alcóxi, arilóxi, aralcoxiarila, aralcoxiheteroarila, heteroarila, heterociclila, heteroarilóxi, -CONR~ 2~R~ 3~, -NR~ 1~COR~ 2~, -NR~ 1~CONR~ 2~R~ 3~, -OCONR~ 2~R~ 3~, -NR~ 1~COOR~ 4~, ou -SO~ 2~R~ 2~, no qual R~ 1~ é hidrogênio, alquila, heterociclilalquila, aralquila ou heteroarilalquila e R~ 2~ e R~ 3~ são independentemente hidrogênio, alquila, heterociclilalquila, aralquila, heteroarilalquila, arila ou heteroarila; ou R~ 2~ e R~ 3~ tomados juntos com o átomo de nitrogênio ao qual eles são ligados formam um anel de 5 a 7 membros, que pode opcionalmente conter outro heteroátomo selecionado de oxigênio, nitrogênio e enxofre; R~ 4~ é alquila, heterociclilalquila, aralquila, arila ou heteroarila; m representa um número inteiro de um a seis; e n representa o número inteiro de um ou dois; e sal farmaceuticamente aceitável destes; composições farmacêuticas compreendendo os referidos compostos e processos para sua preparação; um método de inibição de metaloproteinases de degradação de matriz em mamíferos empregando tais compostos e o uso destes derivados como medicamento. Os compostos de fórmula I são inibidores de metaloproteinases de degradação de matriz e são úteis para o tratamento de condições relacionadas com eles.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1881998A | 1998-02-04 | 1998-02-04 | |
PCT/EP1999/000646 WO1999042443A1 (en) | 1998-02-04 | 1999-02-02 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9909322A true BR9909322A (pt) | 2000-12-05 |
Family
ID=21789936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9909322-7A BR9909322A (pt) | 1998-02-04 | 1999-02-02 | Derivados de sulfonilamino que inibem metaloproteinases de degradação de matriz |
Country Status (18)
Country | Link |
---|---|
US (1) | US6277987B1 (pt) |
EP (2) | EP1918278A1 (pt) |
JP (1) | JP4750272B2 (pt) |
KR (1) | KR20010040698A (pt) |
CN (1) | CN1195735C (pt) |
AU (1) | AU747911B2 (pt) |
BR (1) | BR9909322A (pt) |
CA (1) | CA2318145C (pt) |
HU (1) | HUP0101176A3 (pt) |
ID (1) | ID24957A (pt) |
IL (1) | IL137465A0 (pt) |
NO (1) | NO317977B1 (pt) |
NZ (1) | NZ505968A (pt) |
PL (1) | PL342009A1 (pt) |
RU (1) | RU2208609C2 (pt) |
SK (1) | SK11692000A3 (pt) |
TR (1) | TR200002224T2 (pt) |
WO (1) | WO1999042443A1 (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2327290A1 (en) * | 1998-04-03 | 1999-10-14 | Sankyo Company Limited | Sulfonamide derivatives |
CZ20013176A3 (cs) * | 1999-03-03 | 2002-04-17 | The Procter & Gamble Company | Sloučenina vytvářející inhibitor metaloproteinasy, farmaceutický prostředek, způsob přípravy léčiva a léčivo |
RU2001126719A (ru) | 1999-03-03 | 2004-02-20 | Дзе Проктер Энд Гэмбл Компани (US) | Дигетерозамещенные ингибиторы металлопротеазы |
GB9918684D0 (en) | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
EP1088815A1 (en) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonyl amino acid derivatives |
WO2001023363A1 (fr) * | 1999-09-29 | 2001-04-05 | Sankyo Company, Limited | Derives de sulfonamide |
JP2003528082A (ja) | 2000-03-21 | 2003-09-24 | ザ プロクター アンド ギャンブル カンパニー | ニフッ化酪酸メタロプロテアーゼ阻害物質 |
KR20020081464A (ko) * | 2000-03-21 | 2002-10-26 | 더 프록터 앤드 갬블 캄파니 | 헤테로시클릭 측쇄 함유 메탈로프로테아제 억제제 |
CA2404131A1 (en) | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
AU2001248701A1 (en) * | 2000-03-24 | 2001-10-03 | Methylgene, Inc. | Inhibitors of histone deacetylase |
WO2001083431A1 (fr) * | 2000-04-28 | 2001-11-08 | Shionogi & Co., Ltd. | Inhibiteurs de mmp-12 |
EP1174129A1 (en) * | 2000-07-17 | 2002-01-23 | Zenner, Hans Peter, Prof. Dr. med. | Use of a matrix-metalloprotease inhibitor for the treatment of cancer |
GB0103303D0 (en) | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0103710D0 (sv) | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
JP4427328B2 (ja) * | 2001-12-14 | 2010-03-03 | エクセリクシス, インク. | ヒト−adam−10インヒビター |
US20050227994A1 (en) * | 2002-03-27 | 2005-10-13 | Shionogi & Co., Ltd. | Decomposition inhibitor for extracellular matrix of cartilage |
SI1511472T1 (sl) | 2002-05-29 | 2009-08-31 | Merck & Co Inc | Spojine uporabne pri zdravljenju antraksa in inhibiranju letalnega faktorja |
SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
CN1950354A (zh) | 2004-05-11 | 2007-04-18 | 默克公司 | N-磺酰化-氨基酸衍生物的制备方法 |
GB0412553D0 (en) | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
SE0401762D0 (sv) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
WO2006029173A2 (en) * | 2004-09-08 | 2006-03-16 | Boys Town National Research Hospital | Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12 |
US20100003276A1 (en) * | 2004-12-07 | 2010-01-07 | Hermes Jeffery D | Methods for treating anthrax and inhibiting lethal factor |
SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
SE0403086D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
US7576222B2 (en) * | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
US20100247512A1 (en) * | 2006-03-31 | 2010-09-30 | The Regents Of The University Of Michigan | Pericellular Collagenase Directs the 3-Dimensional Development of White Adipose Tissue |
TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
EP1972617A1 (en) * | 2007-03-19 | 2008-09-24 | Bracco Imaging, S.P.A. | Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors |
GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
CA2719457C (en) * | 2008-03-24 | 2017-05-02 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
EP2147684A1 (en) * | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
EP2149568A1 (en) | 2008-07-22 | 2010-02-03 | Bracco Imaging S.p.A | Aryl-sulphonamidic dimers as metalloproteases inhibitors |
GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
PE20120119A1 (es) * | 2008-12-05 | 2012-03-18 | Abbvie Inc | AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 |
ITTO20090648A1 (it) * | 2009-08-19 | 2011-02-20 | Istituto Naz Per La Ricerca Sul Cancro | Inibitori di adam17 atti a modulare il rilascio di alcam (cd166) solubile in cellule tumorali e loro uso nel trattamento terapeutico del carcinoma ovarico epiteliale (eoc) |
US9023318B2 (en) | 2011-06-08 | 2015-05-05 | Siemens Medical Solutions Usa, Inc. | Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof |
GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
SI3262028T1 (sl) | 2014-12-17 | 2022-02-28 | Pimco 2664 Limited | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidne in N-(-4hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidne spojine in njihova terapevtska uporaba |
CN110483437B (zh) * | 2018-05-14 | 2022-12-06 | 嘉兴维眸生物科技有限公司 | 一种含五元环的化合物及其制备和应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1493665A1 (de) | 1964-07-16 | 1969-02-06 | Hoechst Ag | Verfahren zur Spaltung von aromatischen Carbonsaeureamiden |
EP0639982A1 (en) | 1992-05-01 | 1995-03-01 | British Biotech Pharmaceuticals Limited | Use of mmp inhibitors |
US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5552419A (en) | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
JPH10501806A (ja) | 1994-06-22 | 1998-02-17 | ブリティッシュ バイオテック ファーマシューティカルズ リミテッド | 金属タンパク質分解酵素阻害剤 |
HUP9902083A3 (en) | 1995-11-17 | 2000-06-28 | Warner Lambert Co | Sulfonamide inhibitors of matrix metalloproteinases |
US5753653A (en) | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
ES2195034T3 (es) | 1995-12-08 | 2003-12-01 | Agouron Pharma | Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion. |
NZ325939A (en) * | 1996-01-23 | 2000-06-23 | Shionogi & Co | Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives |
DE69707865T2 (de) * | 1996-05-17 | 2002-05-02 | Warner Lambert Co | Biphenylsulfonamid matrix metalloproteinase inhibitoren |
EP0915086A4 (en) | 1996-05-24 | 2001-01-17 | Ono Pharmaceutical Co | PHENYLSULFONAMIDE DERIVATIVES |
EP0923561B1 (en) | 1996-08-28 | 2002-10-23 | The Procter & Gamble Company | Heterocyclic metalloprotease inhibitors |
BR9713185A (pt) | 1996-08-28 | 1999-11-03 | Procter & Gamble | Inibidores metalo protease heterocìclicos |
BR9712792A (pt) | 1996-08-28 | 1999-12-14 | Procter & Gamble | Inibidores de metaloprotease bidentada. |
JP3541043B2 (ja) | 1996-08-28 | 2004-07-07 | ザ プロクター アンド ギャンブル カンパニー | 置換環状アミンメタロプロテアーゼ阻害剤 |
DE69730033T2 (de) | 1996-08-28 | 2005-07-21 | The Procter & Gamble Company, Cincinnati | Spirocyclisch metalloprotease inhibitoren |
ATE227274T1 (de) | 1996-08-28 | 2002-11-15 | Procter & Gamble | 1,3-diheterozyklische metalloprotease inhibitoren |
AU737117B2 (en) * | 1996-12-17 | 2001-08-09 | Warner-Lambert Company | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing |
CN1243507A (zh) * | 1997-01-17 | 2000-02-02 | 法玛西雅厄普约翰美国公司 | 用作mmp抑制剂的双磺酰胺异羟肟酸类化合物 |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
JP2001521504A (ja) | 1997-04-01 | 2001-11-06 | アグロン・ファーマシュウティカルズ・インコーポレーテッド | メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用 |
US5756545A (en) * | 1997-04-21 | 1998-05-26 | Warner-Lambert Company | Biphenysulfonamide matrix metal alloproteinase inhibitors |
DE19719428A1 (de) | 1997-05-12 | 1998-11-19 | Hoechst Ag | Substituierte Diaminocarbonsäuren |
DE19719585A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Substituierte Diaminocarbonsäuren |
PT877019E (pt) | 1997-05-09 | 2002-05-31 | Hoechst Ag | Acidos diaminocarboxilicos substituidos |
DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
AU7294098A (en) | 1997-05-09 | 1998-11-27 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
IL133933A0 (en) | 1997-07-22 | 2001-04-30 | Shionogi & Co | Composition for treating or preventing glomerulopathy |
WO1999006340A2 (en) * | 1997-07-31 | 1999-02-11 | The Procter & Gamble Company | Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors |
-
1999
- 1999-02-02 EP EP07120827A patent/EP1918278A1/en not_active Withdrawn
- 1999-02-02 IL IL13746599A patent/IL137465A0/xx unknown
- 1999-02-02 SK SK1169-2000A patent/SK11692000A3/sk unknown
- 1999-02-02 CN CNB998027154A patent/CN1195735C/zh not_active Expired - Fee Related
- 1999-02-02 ID IDW20001501A patent/ID24957A/id unknown
- 1999-02-02 BR BR9909322-7A patent/BR9909322A/pt not_active IP Right Cessation
- 1999-02-02 RU RU2000123166/04A patent/RU2208609C2/ru not_active IP Right Cessation
- 1999-02-02 KR KR1020007008576A patent/KR20010040698A/ko not_active Application Discontinuation
- 1999-02-02 PL PL99342009A patent/PL342009A1/xx not_active Application Discontinuation
- 1999-02-02 NZ NZ505968A patent/NZ505968A/xx unknown
- 1999-02-02 CA CA002318145A patent/CA2318145C/en not_active Expired - Fee Related
- 1999-02-02 TR TR2000/02224T patent/TR200002224T2/xx unknown
- 1999-02-02 AU AU29235/99A patent/AU747911B2/en not_active Ceased
- 1999-02-02 WO PCT/EP1999/000646 patent/WO1999042443A1/en not_active Application Discontinuation
- 1999-02-02 HU HU0101176A patent/HUP0101176A3/hu unknown
- 1999-02-02 JP JP2000532395A patent/JP4750272B2/ja not_active Expired - Fee Related
- 1999-02-02 EP EP99910174A patent/EP1053226A1/en not_active Ceased
- 1999-02-03 US US09/243,854 patent/US6277987B1/en not_active Expired - Fee Related
-
2000
- 2000-07-11 NO NO20003565A patent/NO317977B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2318145C (en) | 2009-10-27 |
RU2208609C2 (ru) | 2003-07-20 |
CN1290250A (zh) | 2001-04-04 |
JP4750272B2 (ja) | 2011-08-17 |
WO1999042443A1 (en) | 1999-08-26 |
CN1195735C (zh) | 2005-04-06 |
EP1918278A1 (en) | 2008-05-07 |
TR200002224T2 (tr) | 2000-12-21 |
NO317977B1 (no) | 2005-01-17 |
IL137465A0 (en) | 2001-07-24 |
EP1053226A1 (en) | 2000-11-22 |
CA2318145A1 (en) | 1999-08-26 |
NO20003565D0 (no) | 2000-07-11 |
SK11692000A3 (sk) | 2001-02-12 |
PL342009A1 (en) | 2001-05-07 |
NO20003565L (no) | 2000-10-03 |
AU2923599A (en) | 1999-09-06 |
NZ505968A (en) | 2003-03-28 |
US6277987B1 (en) | 2001-08-21 |
ID24957A (id) | 2000-08-31 |
JP2002503720A (ja) | 2002-02-05 |
AU747911B2 (en) | 2002-05-30 |
HUP0101176A3 (en) | 2002-06-28 |
HUP0101176A2 (hu) | 2001-09-28 |
KR20010040698A (ko) | 2001-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9909322A (pt) | Derivados de sulfonilamino que inibem metaloproteinases de degradação de matriz | |
EA200100230A1 (ru) | Производные 1h-имидазопиридина | |
BRPI0014526B8 (pt) | compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo | |
RU2002125860A (ru) | Новые производные циклического амида | |
KR910006218A (ko) | 2-아미도테트라린 치환유도체와 이 치환유도체를 포함하는 제약학적 조성물 및 이를 사용한 치료방법 | |
BRPI0014382B8 (pt) | piridinas e piridazinas substituídas com atividade de inibição de angiogênese bem como composições farmacêuticas compreendendo os mesmos | |
DE69433148D1 (de) | Tricyclische kondensierte heterocyclische Verbindungen zur Behandlung von seniler Demenz | |
RO93855A (ro) | Procedeu pentru prepararea de arilciclobutilalchilamina | |
AR241422A1 (es) | Procedimiento para la preparacion de derivados de difenil(metil-etil-0 etenil) piperidinas. | |
ATE127117T1 (de) | 1-aryl-1-hydroxy-1-substituierte-3-(4- substituierte-1-piperazinyl)-2-propanone und ihre verwendung bei der behandlung von blasenstörungen neurologischen ursprungs. | |
DE69329084T2 (de) | Benzoxazepin-Derivate als Cholinesterase-Inhibitoren | |
KR880009957A (ko) | 알킬-치환된 n-벤조피라닐락탐, 이의 제조방법, 이의 용도 및 이들 화합물을 기본으로 하는 약제학적 제제 | |
US3888983A (en) | Derivatives of thiazolino-pyrimidin-6-ones, in inducing analgesia | |
DE69011781D1 (de) | 1-acyl-2-pyrrolidinone zur Verbesserung der Lernfähigkeit und des Gedächtnisses und diese enthaltende pharmazeutische Zubereitungen. | |
ATE8389T1 (de) | Amino-alkoxy-pyrazole, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
ATE104298T1 (de) | Kondensierte heterocyclische derivate von 1,2,3,4-tetrahydroacridin, verfahren zu ihrer herstellung und ihre verwendung als medikament. | |
NO984547L (no) | Nye oksazolidinderivater, fremgangsmÕte for deres fremstilling, samt legemidler inneholdende disse forbindelser | |
ES454285A1 (es) | Procedimiento para preparar derivados de 4-amina trans-deca-hidroquinolina. | |
DK99588A (da) | 2-(aminoalkythio)methyl-1,4-dihydropyridin-forbindelser, en fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem | |
TH25787A (th) | เอสเทอร์และแอมีดของได-ซับสทิทิวเทด 1,4-พิเพอริดีน | |
TH13838EX (th) | สิ่งเคลือบบนกระจก | |
RU99115884A (ru) | Пролекарственные формы и новые аналоги камптотецина, их применение в качестве лекарственных средств | |
TH8799EX (th) | การใช้อนุพันธ์ของอิมิแดโซพิแรโซลเป็นสารแก้ปวดและต่อต้านการอักเสบ | |
TH9548B (th) | "การใช้ประโยชน์ของอนุพันธ์ของลิกแนนสำหรับการเตรียมสารผสมทางเภสัชสำหรับการบำบัดรักษาสถานะของการพอกจับตัวของแอมิลอยด์" | |
TH7138A (th) | ไฮดราไซด์ และอนุพันธ์กรดไฮดรอกซามิค |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007. |